John Luckey, MD
Family Medicine · Sterling, ILNPI 1629230768
Payments from drug & device makers
Across 115 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$401
- Pfizer$152
- AbbVie$130
- AstraZeneca$129
- Lilly USA, LLC$115
- Supernus Pharmaceuticals, Inc.$70
- plus $836 from 20 others
What the payments were for
- Food & beverage$1,82199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $401 |
| Pfizer | 10 | $152 |
| AbbVie(2 entities) | 7 | $130 |
| AstraZeneca | 8 | $129 |
| Lilly USA, LLC | 8 | $115 |
| Supernus Pharmaceuticals, Inc. | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Abbott | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| GSK | 4 | $59 |
| Boehringer Ingelheim | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Johnson & Johnson | 4 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 4 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Mylan Specialty L.p. | 3 | $45 |
| Merck | 3 | $41 |
| Amgen | 2 | $32 |
| Bayer | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
| Medtronic | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$1,832 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $222,338 |
| EliquisApixaban | 87 | $85,050 |
| MounjaroTirzepatide | 70 | $78,964 |
| JardianceEmpagliflozin | 54 | $71,292 |
| FarxigaDapagliflozin Propanediol | 50 | $46,819 |
| XareltoRivaroxaban | 41 | $42,791 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $34,598 |
| JanuviaSitagliptin Phosphate | 21 | $34,283 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $31,188 |
| RexultiBrexpiprazole | 18 | $29,386 |
| TrulicityDulaglutide | 12 | $19,154 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $11,116 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 205 | $6,927 |
| Varenicline Tartrate | 12 | $6,424 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $401 | $222,338153 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $115 | $100,69494 claims |
| PfizerEliquis | $152 | $85,05087 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $56 | $76,88065 claims |
| AstraZenecaFarxiga, Symbicort | $129 | $50,29665 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $59 | $47,16055 claims |
| Johnson & JohnsonXarelto | $51 | $42,79141 claims |
| MerckJanuvia | $41 | $34,28321 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $55 | $29,38618 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $15 | $5,67711 claims |
| AbbVieSynthroid | $130 | $1,95118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Sterling
- Peter TothSterling$1.4M
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.